Tier 2 — strong
Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
The American journal of cardiology
2003
92(2):173-176
Bibliography
- PubMed
- PMID 12860219
- Funding
- Funding was not established from the accessible source; this is not a declaration of no funding.
- Competing interests
- A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.
Study snapshot
| Design | Randomized controlled human trial |
|---|---|
| Model | Human participants; see population |
| Sample | 156 patients; 79 berberine and 77 placebo |
| Intervention | Berberine 1.2–2 g/day added to then-standard heart-failure therapy |
| Duration | 8-week initial assessment; mean 24-month follow-up |
| Endpoints | Ejection fraction and exercise capacity; Ventricular ectopy; Symptoms, quality of life and follow-up deaths |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Berberine and Blood Pressure: Evidence and Medication QuestionsDoes berberine lower blood pressure? Examine human trials, mixed findings, medication questions, measurement pitfalls and why cardiovascular claims differ.Read analysis
- Berberine Benefits: What Human Studies Actually ShowExplore berberine benefits for blood sugar, cholesterol, weight and gut health, with human trial results, 2026 updates, safety and formulation differences.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
